fluorouracil has been researched along with Cancer of Digestive System in 68 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The feasibility, safety, and efficacy of planned sequential administration of docetaxel and irinotecan with 5-fluorouracil (5-FU)/leucovorin in advanced upper gastrointestinal adenocarcinoma (UGIA) are unknown." | 5.14 | An explorative randomised phase II study of sequential chemotherapy in advanced upper gastrointestinal cancer. ( Berglund, A; Byström, P; Frödin, JE; Glimelius, B; Johansson, B; Letocha, H; Nygren, P; Pedersen, D, 2010) |
| "We have reported a 33% partial response rate with acceptable toxicity using weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) and leucovorin (LV) in patients with far advanced biliary tract cancers (BTC)." | 5.09 | Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas. ( Chen, JS; Jan, YY; Liau, CT; Lin, YC, 2001) |
| " Fifty-five breast cancer patients treated with mitoxantrone, methotrexate and 5-fluorouracil gave a response rate of 52." | 5.06 | [Mitoxantrone containing multi-drug chemotherapy in the management of malignancies. Collaborative Group for Clinical Trial of Mitoxantrone]. ( , 1989) |
| "Capecitabine was increased until the appearance of dose limiting toxicities (DLTs)." | 2.75 | Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies. ( Cheng, YC; Elligers, K; Grant, N; Jiang, ZL; Lamb, L; Lansigan, F; Liu, SH; Mezes, M; Ruta, S; Saif, MW, 2010) |
| " The objective of this Phase I study was to define the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of imatinib in combination with fluorouracil and leucovorin in patients with chemotherapy-refractory gastrointestinal cancer." | 2.73 | Imatinib mesylate for targeting the platelet-derived growth factor beta receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer--a dose-escalation Phase I trial. ( Al-Batran, SE; Atmaca, A; Ehninger, G; Hosius, C; Jäger, E; Pauligk, C; Schleyer, E, 2007) |
| " For irinotecan, SN-38, APC and NPC, similar pharmacokinetic profiles were observed from plasma and saliva data." | 2.72 | Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen. ( Abderrahim, AG; Astre, C; Bressolle, F; Duffour, J; Pinguet, F; Poujol, S; Ychou, M, 2006) |
| "For 27 outpatients with advanced cancer of the digestive system including 15 cases of esophageal cancer, 4 cases of gastric cancer, 3 cases of colon cancer, 4 cases of pancreatic cancer and 1 case of gall bladder cancer, 4 to 6 week home adjuvant chemotherapy was performed." | 2.68 | [Combined chemotherapy with 5-FU and low dose CDDP for advanced or recurrent cancer of the digestive system and home anti-cancer chemotherapy]. ( Araki, H; Hiramatsu, Y; Kamiyama, Y; Kojima, Y; Nakagawa, A; Nakagawa, M; Ogura, T; Shirasaka, T, 1995) |
| "Trimetrexate (TMTX) is a dihydrofolate reductase inhibitor, which, like methotrexate (MTX), has been shown to potentiate fluorouracil (FU) cytotoxicity by increasing phosphoribosylpyrophosphate (PRPP) levels." | 2.67 | Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma. ( André, M; Bertino, JR; Conti, JA; Goker, E; Kemeny, N; Ragusa, K; Seiter, K; Tong, W, 1994) |
| "00001), and can reduce adverse drug reactions (ADRs) such as myelosuppression (RR = 0." | 2.66 | Kanglaite injection plus fluorouracil-based chemotherapy on the reduction of adverse effects and improvement of clinical effectiveness in patients with advanced malignant tumors of the digestive tract: A meta-analysis of 20 RCTs following the PRISMA guide ( Leung, EL; Li, G; Song, Q; Wu, Q; Zhang, J, 2020) |
| "Capecitabine has been developed as a prodrug of FU, with the goal of improving tolerability and intratumor drug concentration through tumor-specific conversion to the active drug." | 2.45 | The role of capecitabine in the management of tumors of the digestive system. ( Gennatas, C; Gennatas, S; Michalaki, V, 2009) |
| "Gemcitabine is a well-tolerated anti-tumour drug with broad-spectrum activity." | 2.44 | [Gemcitabine and digestive carcinomas]. ( André, T; Blanchard, P; Huguet, F, 2007) |
| "Pretreatment 5-fluorouracil (5-FU) degradation rate and DPYD, TSER, MTHFR A1298T, and C677T gene polymorphisms were characterized." | 1.46 | A nomogram to predict 5-fluorouracil toxicity: when pharmacogenomics meets the patient. ( Anselmi, E; Borro, M; Botticelli, A; Cerbelli, B; Di Pietro, FR; Falcone, R; Gentile, G; Lionetto, L; Macrini, S; Marchetti, P; Mazzuca, F; Milano, A; Occhipinti, M; Onesti, CE; Petremolo, A; Roberto, M; Simmaco, M; Strigari, L, 2017) |
| " Dihydropyrimidine dehydrogenase (DPD) deficiency is a pharmacogenetic syndrome responsible for most cases of life-threatening toxicities upon 5-FU intake, and pre-treatment checking for DPD status should help to reduce both incidence and severity of side effects through adaptive dosing strategies." | 1.43 | Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer. ( Ciccolini, J; Dahan, L; Duluc, M; Duval, M; Lacarelle, B; Launay, M; Milano, G; Rodallec, A; Seitz, JF, 2016) |
| "Among the 252 cases, there were 110 carcinoids (43." | 1.39 | [Neuroendocrine tumors: analysis of 252 cases]. ( Chi, YH; Du, F; Jiang, WC; Song, Y; Sun, YK; Wang, JW; Yang, L; Zhou, AP, 2013) |
| "In this study we propose for the first time a limited sampling strategy to estimate the individual pharmacokinetic parameters of both irinotecan and SN-38 in patients treated with the irinotecan plus 5-fluorouracil (FOLFIRI) regimen." | 1.34 | A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen. ( Abderrahim, AG; Bressolle, FM; Duffour, J; Pinguet, F; Poujol, S; Ychou, M, 2007) |
| "Improvement of oral mucositis was associated with a significant decrease of intestinal permeability to lactulose." | 1.31 | Intestinal permeability in patients with chemotherapy-induced stomatitis. ( Brátová, M; Kohout, P; Králícková, P; Melichar, B; Solichová, D; Zadák, Z, 2001) |
| "Oral mucositis is a dose-limiting toxicity of 5-fluorouracil (5-FU)." | 1.30 | Risk factors associated with mucositis in cancer patients receiving 5-fluorouracil. ( Awde, JD; Ghandi, H; Kocha, WI; McCarthy, GM; Vincent, M, 1998) |
| " Continuous intravenous infusion of 5-FU (300-400 mg/body/day) combined with low-dose injection of cisplatin (5 mg/body/day) was continued for 10 days, and repeated 3 times for 6 weeks." | 1.30 | [Home anti-cancer chemotherapy with continuous infusion of 5-FU combined with low-dose cisplatin injection via implantable venous port with portable balloon pump]. ( Ashino, Y; Kanno, A; Kanzaki, N; Kawahara, Y; Miyazawa, M; Muto, A; Sato, M, 1999) |
| "Primary tumours were carcinoids in nine, gastrinomas in five, non-functioning pancreatic tumours in six and calcitonin-secreting tumours in two patients." | 1.29 | Liver metastases of digestive endocrine tumours: natural history and response to medical treatment. ( Bernades, P; Menu, Y; Ruszniewski, P; Skinazi, F; Zins, M, 1996) |
| "A series of 344 patients with squamous cell carcinoma (oropharynx, larynx, hypopharynx, or buccal cavity) were treated between November 1982 and January 1985 by chemotherapy." | 1.27 | [Induction chemotherapy in cancers of the respiratory and digestive tracts by continuous infusions combining cisplatinum (C), fluorouracil (F), bleomycin (B) or C and F]. ( Bassot, V; Brasnu, D; Donnadieu, S; Fabre, A; Jacquillat, C; Lacau-St-Guily, J; Laccourreye, H; Menard, M, 1986) |
| " Toxic effects are specially considered in this paper, where effects in 20 advanced gastrointestinal patients are evaluated." | 1.27 | [5-fluorouracil in high doses. Principles and toxicity]. ( Fleischer, I; Milano, MC; Wainstein, R, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (25.00) | 18.7374 |
| 1990's | 24 (35.29) | 18.2507 |
| 2000's | 17 (25.00) | 29.6817 |
| 2010's | 8 (11.76) | 24.3611 |
| 2020's | 2 (2.94) | 2.80 |
| Authors | Studies |
|---|---|
| Song, Q | 1 |
| Zhang, J | 1 |
| Wu, Q | 1 |
| Li, G | 1 |
| Leung, EL | 1 |
| Gui, Q | 1 |
| Li, D | 1 |
| Zhuge, Y | 1 |
| Xu, C | 1 |
| Loriot, MA | 1 |
| Masskouri, F | 1 |
| Carni, P | 1 |
| Le Malicot, K | 1 |
| Seitz, JF | 3 |
| Michel, P | 2 |
| Legoux, JL | 1 |
| Bouché, O | 1 |
| André, T | 2 |
| Faroux, R | 1 |
| Delaloge, S | 1 |
| Malka, D | 1 |
| Guigay, J | 1 |
| Thariat, J | 1 |
| Thomas, F | 1 |
| Barin-Le-Guellec, C | 1 |
| Ciccolini, J | 3 |
| Boyer, JC | 1 |
| Étienne-Grimaldi, MC | 1 |
| Chi, YH | 1 |
| Jiang, WC | 1 |
| Du, F | 1 |
| Sun, YK | 1 |
| Song, Y | 1 |
| Yang, L | 1 |
| Zhou, AP | 1 |
| Wang, JW | 1 |
| Kesavan, M | 1 |
| Claringbold, PG | 1 |
| Turner, JH | 1 |
| Launay, M | 1 |
| Dahan, L | 1 |
| Duval, M | 1 |
| Rodallec, A | 1 |
| Milano, G | 3 |
| Duluc, M | 1 |
| Lacarelle, B | 1 |
| Botticelli, A | 1 |
| Onesti, CE | 1 |
| Strigari, L | 1 |
| Occhipinti, M | 1 |
| Di Pietro, FR | 1 |
| Cerbelli, B | 1 |
| Petremolo, A | 1 |
| Anselmi, E | 1 |
| Macrini, S | 1 |
| Roberto, M | 1 |
| Falcone, R | 1 |
| Lionetto, L | 1 |
| Borro, M | 1 |
| Milano, A | 1 |
| Gentile, G | 1 |
| Simmaco, M | 1 |
| Marchetti, P | 1 |
| Mazzuca, F | 1 |
| Ea, S | 1 |
| Giacometti, S | 1 |
| Akhmedjanova, V | 1 |
| Aubert, C | 2 |
| Christante, D | 1 |
| Pommier, S | 1 |
| Givi, B | 1 |
| Pommier, R | 1 |
| Gennatas, C | 1 |
| Michalaki, V | 1 |
| Gennatas, S | 1 |
| Berglund, A | 1 |
| Byström, P | 1 |
| Johansson, B | 1 |
| Nygren, P | 1 |
| Frödin, JE | 1 |
| Pedersen, D | 1 |
| Letocha, H | 1 |
| Glimelius, B | 1 |
| Ku, GY | 1 |
| O'Reilly, EM | 1 |
| Saltz, LB | 1 |
| Schrag, D | 1 |
| Maki, RG | 1 |
| Kelsen, DP | 1 |
| Ilson, DH | 1 |
| Saif, MW | 1 |
| Lansigan, F | 1 |
| Ruta, S | 1 |
| Lamb, L | 1 |
| Mezes, M | 1 |
| Elligers, K | 1 |
| Grant, N | 1 |
| Jiang, ZL | 1 |
| Liu, SH | 1 |
| Cheng, YC | 1 |
| Brierley, R | 1 |
| WEISS, AJ | 1 |
| JACKSON, L | 1 |
| Correale, P | 1 |
| Cerretani, D | 1 |
| Clerici, M | 1 |
| Messinese, S | 1 |
| Marsili, S | 1 |
| Petrioli, R | 1 |
| Cetta, F | 1 |
| Savelli, V | 1 |
| Guarnieri, A | 1 |
| Pinto, E | 1 |
| Giorgi, G | 1 |
| Francini, G | 1 |
| Delaunoit, T | 1 |
| Maréchal, R | 1 |
| Hendlisz, A | 2 |
| Eisendrath, P | 1 |
| Legendre, H | 1 |
| Pector, JC | 1 |
| De Becker, D | 1 |
| Bleiberg, H | 2 |
| Poujol, S | 2 |
| Bressolle, F | 1 |
| Duffour, J | 2 |
| Abderrahim, AG | 2 |
| Astre, C | 1 |
| Ychou, M | 2 |
| Pinguet, F | 2 |
| Al-Batran, SE | 1 |
| Atmaca, A | 1 |
| Schleyer, E | 1 |
| Pauligk, C | 1 |
| Hosius, C | 1 |
| Ehninger, G | 1 |
| Jäger, E | 1 |
| Blanchard, P | 1 |
| Huguet, F | 1 |
| Bressolle, FM | 1 |
| Ceppi, P | 1 |
| Volante, M | 1 |
| Ferrero, A | 1 |
| Righi, L | 1 |
| Rapa, I | 1 |
| Rosas, R | 1 |
| Berruti, A | 1 |
| Dogliotti, L | 1 |
| Scagliotti, GV | 1 |
| Papotti, M | 1 |
| Maeta, M | 1 |
| Koga, S | 1 |
| Yamane, T | 1 |
| Shimizu, N | 1 |
| Oda, M | 1 |
| Masaki, T | 1 |
| Yoshida, Y | 1 |
| Watnabe, S | 1 |
| Tanida, O | 1 |
| Kishimoto, H | 1 |
| Ibayashi, J | 1 |
| Joveniaux, A | 1 |
| Caty, A | 1 |
| Adenis, L | 1 |
| Cano, JP | 1 |
| Rigault, JP | 1 |
| Carcassonne, Y | 1 |
| Conti, JA | 1 |
| Kemeny, N | 1 |
| Seiter, K | 1 |
| Goker, E | 1 |
| Tong, W | 1 |
| André, M | 1 |
| Ragusa, K | 1 |
| Bertino, JR | 1 |
| Pu, AT | 1 |
| Robertson, JM | 1 |
| Lawrence, TS | 1 |
| Hamilton, JM | 2 |
| Beck, A | 2 |
| Etienne, MC | 2 |
| Chéradame, S | 2 |
| Fischel, JL | 2 |
| Formento, P | 2 |
| Renée, N | 1 |
| Guillot, T | 1 |
| McLachlan, SA | 1 |
| Millward, MJ | 1 |
| Toner, GC | 1 |
| Guiney, MJ | 1 |
| Bishop, JF | 1 |
| Labianca, R | 1 |
| Pancera, G | 1 |
| Barni, S | 1 |
| Cascinu, S | 1 |
| Comella, G | 2 |
| Foa, P | 1 |
| Martignoni, G | 1 |
| Zaniboni, A | 1 |
| Giaccon, G | 1 |
| Luporini, G | 1 |
| Setiz, JF | 1 |
| Perrier, H | 1 |
| Giovannini, M | 1 |
| Thill, L | 1 |
| Gutman, M | 1 |
| Abu-Abid, S | 1 |
| Sorkine, P | 1 |
| Inbar, M | 1 |
| Lev, D | 1 |
| Chen, Z | 1 |
| Oron, D | 1 |
| Chaitchik, S | 1 |
| Klausner, JM | 1 |
| Ogura, T | 1 |
| Hiramatsu, Y | 1 |
| Araki, H | 1 |
| Kojima, Y | 1 |
| Nakagawa, A | 1 |
| Nakagawa, M | 1 |
| Kamiyama, Y | 1 |
| Shirasaka, T | 1 |
| Skinazi, F | 1 |
| Zins, M | 1 |
| Menu, Y | 1 |
| Bernades, P | 1 |
| Ruszniewski, P | 1 |
| Comella, P | 1 |
| Palmieri, G | 1 |
| Lorusso, V | 1 |
| Catalano, G | 1 |
| Nicollela, D | 1 |
| Ianniello, GP | 1 |
| Casaretti, R | 1 |
| Montella, M | 1 |
| Frasci, G | 1 |
| Perna, M | 1 |
| John, WJ | 1 |
| Foon, KA | 1 |
| McCarthy, GM | 1 |
| Awde, JD | 1 |
| Ghandi, H | 1 |
| Vincent, M | 1 |
| Kocha, WI | 1 |
| Takimoto, CH | 1 |
| Yee, LK | 2 |
| Venzon, DJ | 1 |
| Schuler, B | 1 |
| Grollman, F | 1 |
| Chabuk, C | 1 |
| Chen, AP | 1 |
| Allegra, CJ | 2 |
| Grem, JL | 2 |
| Ikehira, H | 1 |
| Girard, F | 1 |
| Obata, T | 1 |
| Ito, H | 2 |
| Yoshitomi, H | 1 |
| Miyazaki, M | 1 |
| Nakajima, N | 1 |
| Kamei, H | 1 |
| Kanazawa, Y | 1 |
| Takano, H | 1 |
| Tanada, S | 1 |
| Sasaki, Y | 1 |
| Muto, A | 2 |
| Ashino, Y | 2 |
| Sato, M | 2 |
| Miyazawa, M | 2 |
| Kanno, A | 2 |
| Kanzaki, N | 1 |
| Kawahara, Y | 2 |
| Fujita, Y | 1 |
| Matsushiro, T | 1 |
| Chen, JS | 1 |
| Lin, YC | 1 |
| Jan, YY | 1 |
| Liau, CT | 1 |
| Melichar, B | 1 |
| Kohout, P | 1 |
| Brátová, M | 1 |
| Solichová, D | 1 |
| Králícková, P | 1 |
| Zadák, Z | 1 |
| Caroli-Bosc, FX | 1 |
| Van Laethem, JL | 1 |
| Gay, F | 1 |
| Forget, F | 1 |
| Aparicio, T | 1 |
| Ducreux, M | 1 |
| Chaussade, S | 1 |
| Xu, D | 1 |
| Chen, G | 1 |
| Li, S | 1 |
| Cai, Y | 1 |
| Chen, H | 1 |
| Ling, H | 1 |
| Li, Z | 1 |
| Zeitoun, P | 1 |
| Martin, F | 1 |
| Nasca, S | 1 |
| Nio, Y | 1 |
| Kimura, H | 1 |
| Tsubono, M | 1 |
| Tseng, CC | 1 |
| Kawabata, K | 1 |
| Masai, Y | 1 |
| Hayashi, H | 1 |
| Araya, S | 1 |
| Meyer, C | 1 |
| Fukumoto, M | 1 |
| Steinberg, SM | 1 |
| Sasaki, T | 1 |
| Oota, K | 1 |
| Shparyk, IaV | 1 |
| Cappelaere, P | 1 |
| Vignoud, J | 1 |
| Fargeot, P | 1 |
| Metz, R | 1 |
| Chauvergne, J | 1 |
| Meeus, L | 1 |
| Schneider, M | 1 |
| Chazard, M | 1 |
| Bhalla, K | 1 |
| Birkhofer, M | 1 |
| Bhalla, M | 1 |
| Lutzky, J | 1 |
| Hindenburg, A | 1 |
| Cole, J | 1 |
| Ince, C | 1 |
| Bassot, V | 1 |
| Brasnu, D | 1 |
| Lacau-St-Guily, J | 1 |
| Fabre, A | 1 |
| Menard, M | 1 |
| Donnadieu, S | 1 |
| Jacquillat, C | 1 |
| Laccourreye, H | 1 |
| Seo, Y | 1 |
| Hara, Y | 1 |
| Furusawa, M | 1 |
| Nakane, H | 1 |
| Saeki, K | 1 |
| Tsujitani, S | 1 |
| Sonoda, T | 1 |
| Nohtsuka, T | 1 |
| Kameda, K | 1 |
| Tomoda, H | 1 |
| Soga, K | 1 |
| Turuya, T | 1 |
| Toshima, M | 1 |
| Shibasaki, K | 1 |
| Matugi, H | 1 |
| Kawai, C | 1 |
| Asakura, H | 1 |
| Nashimoto, A | 1 |
| Sasaki, J | 1 |
| Kato, K | 1 |
| Tsutsui, M | 1 |
| Sano, M | 1 |
| Akai, S | 1 |
| Maehara, Y | 1 |
| Sakaguchi, Y | 1 |
| Kusumoto, T | 1 |
| Kusumoto, H | 1 |
| Sugimachi, K | 1 |
| Cachin, Y | 1 |
| Domenge, C | 1 |
| Fleischer, I | 2 |
| Wainstein, R | 2 |
| Milano, MC | 1 |
| o, MC | 1 |
| Borisov, VI | 1 |
| Mamontov, AS | 1 |
| Ass, NIa | 1 |
| Sroczyński, J | 1 |
| Wegiel, A | 1 |
| Nałogowska, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Trial of Irinotecan, Cisplatin, and Fluorouracil in Patients With Advanced Solid Tumor Malignancies[NCT00005791] | Phase 1 | 0 participants | Interventional | 1999-10-31 | Completed | ||
| A Phase II Randomized Placebo-Controlled Study Investigating The Combination Of YIV-906 And Sorafenib (Nexavar®) In HBV (+) Patients With Advanced Hepatocellular Carcinoma[NCT04000737] | Phase 2 | 125 participants (Anticipated) | Interventional | 2020-01-10 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for fluorouracil and Cancer of Digestive System
| Article | Year |
|---|---|
Kanglaite injection plus fluorouracil-based chemotherapy on the reduction of adverse effects and improvement of clinical effectiveness in patients with advanced malignant tumors of the digestive tract: A meta-analysis of 20 RCTs following the PRISMA guide
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Digestive System Ne | 2020 |
The role of capecitabine in the management of tumors of the digestive system.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms | 2009 |
[Gemcitabine and digestive carcinomas].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopl | 2007 |
Current status of radiation sensitization by fluoropyrimidines.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Combined Modality Therapy; Diges | 1995 |
Adjuvant therapy for gastrointestinal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clini | 1994 |
Biochemical modulation of fluoropyrimidines: the "GISCAD" studies. GISCAD (Italian Group for the Study of Digestive Tract Cancer).
Topics: Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Digestive System | 1993 |
[Use of 5-fluorouracil in digestive cancer].
Topics: Antimetabolites, Antineoplastic; Digestive System Neoplasms; Drug Interactions; Fluorouracil; Humans | 1996 |
Interferon use in solid tumors.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Smal | 1998 |
[5-fluorouracil: metabolism and current indications in digestive cancer treatment].
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Digestive System Neoplasms; Drug Resista | 2002 |
[Chemotherapy of tumors of the gastrointestinal tract].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Digestive System Neoplasms | 1985 |
21 trials available for fluorouracil and Cancer of Digestive System
| Article | Year |
|---|---|
Efficacy of Exercise Rehabilitation Program in Relieving Oxaliplatin Induced Peripheral Neurotoxicity.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Digestiv | 2021 |
Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Blood Platelets; Capecitabine; Dacarbazine; Deoxycytidin | 2014 |
An explorative randomised phase II study of sequential chemotherapy in advanced upper gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2010 |
Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diarrhea; Dige | 2009 |
Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2010 |
Gemcitabine (GEM), 5-fluorouracil (5-FU) and folinic acid (FA) in patients with different gastroenteric malignancies.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deox | 2004 |
Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Digestive System Neo | 2006 |
Imatinib mesylate for targeting the platelet-derived growth factor beta receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer--a dose-escalation Phase I trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamid | 2007 |
[Chemotherapy of extensive digestive cancers with 5-fluorouracil: relation between the clinical response and plasma clearance of the drug].
Topics: Adult; Aged; Digestive System Neoplasms; Female; Fluorouracil; Humans; Kinetics; Male; Metabolic Cle | 1983 |
Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Digestive System | 1994 |
Regional perfusion with hemofiltration (chemofiltration) for the treatment of patients with regionally advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 1996 |
[Combined chemotherapy with 5-FU and low dose CDDP for advanced or recurrent cancer of the digestive system and home anti-cancer chemotherapy].
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 1995 |
Double biochemical modulation of 5-fluorouracil by methotrexate and levo-folinic acid in the treatment of advanced digestive tract malignancies.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Digestive System Neoplasms; Drug Syner | 1996 |
Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Bilia | 2001 |
A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU)+leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Dig | 2001 |
[Combined high dose leucovorin and 5-fluorouracil continuous infusion for head-neck and digestive tract cancers].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Digestive System Neoplasms; Drug Th | 2002 |
[Treatment of digestive system neoplasms by biochemical modulation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Digestive System Neoplasms; Drug Synergism; Fluorour | 1992 |
[Palliative chemotherapy of epidermoid carcinoma of the upper respiratory and digestive tracts with a combination of carboplatin and 5-fluorouracil].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1990 |
A phase I study of a combination of allopurinol, 5-fluorouracil and leucovorin followed by hydroxyurea in patients with advanced gastrointestinal and breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Digestive System Neoplasms; | 1991 |
[Mitoxantrone containing multi-drug chemotherapy in the management of malignancies. Collaborative Group for Clinical Trial of Mitoxantrone].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Digestive System Neoplasms; | 1989 |
[Chemotherapy of tumors of the gastrointestinal tract].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Digestive System Neoplasms | 1985 |
38 other studies available for fluorouracil and Cancer of Digestive System
| Article | Year |
|---|---|
[Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biology; Biomedical | 2019 |
[Neuroendocrine tumors: analysis of 252 cases].
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoc | 2013 |
Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Digestive System Neoplasms; Dihydro | 2016 |
A nomogram to predict 5-fluorouracil toxicity: when pharmacogenomics meets the patient.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2017 |
Cytotoxic effects of haplamine and its major metabolites on human cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma; Cell Line, | 2008 |
Hepatic artery chemoinfusion with chemoembolization for neuroendocrine cancer with progressive hepatic metastases despite octreotide therapy.
Topics: Adenoma, Islet Cell; Adult; Aged; Antineoplastic Agents; Carcinoid Tumor; Chemoembolization, Therape | 2008 |
14th World Congress on Gastrointestinal Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Digestive System Neoplasms; D | 2012 |
The effect of 5-fluorouracil upon carcinomas of the gastrointestinal tract and related organs.
Topics: Biliary Tract; Biliary Tract Neoplasms; Digestive System Neoplasms; Fluorouracil; Gastrointestinal T | 1961 |
Treatment of advanced digestive non-colon cancer with a weekly 24-h infusion of high-dose 5-fluorouracil modulated by folinic acid and cisplatin: an easy-to-use and well-tolerated combination.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Ci | 2004 |
A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Body | 2007 |
Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors.
Topics: Antineoplastic Agents; Digestive System Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Exp | 2008 |
[Combination chemotherapy with neocarzinostatin(NCS), HCFU and picibanil(NHO therapy) for advanced carcinoma of the digestive system--a comparative study with NF, and NFO therapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Digestive System Neoplasms; Drug Admini | 1984 |
[Cooperative phase II study of releasing tegafur (SF-SP) against advanced digestive cancers].
Topics: Administration, Oral; Adult; Aged; Colonic Neoplasms; Delayed-Action Preparations; Digestive System | 1984 |
[Combination of cisplatin with 5-fluorouracil in the primary treatment of advanced carcinoma of the upper respiratory and digestive tract].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Digestive System Neoplasms; Fluorouracil; | 1984 |
A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil.
Topics: Breast Neoplasms; Digestive System Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Fluorourac | 1994 |
Wide range for optimal concentration of folinic acid in fluorouracil modulation--experimental data on human tumour cell lines.
Topics: Breast Neoplasms; Cell Division; Digestive System Neoplasms; Dose-Response Relationship, Drug; Drug | 1994 |
The spectrum of 5-fluorouracil cardiotoxicity.
Topics: Adenoma; Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; Digestive System Neoplasms; Fema | 1994 |
Liver metastases of digestive endocrine tumours: natural history and response to medical treatment.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Chemoemboliz | 1996 |
Risk factors associated with mucositis in cancer patients receiving 5-fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cohort Studies; Digestive System Ne | 1998 |
High inter- and intrapatient variation in 5-fluorouracil plasma concentrations during a prolonged drug infusion.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chronotherapy; Colonic Neoplasms; Digestive System Neo | 1999 |
A preliminary study for clinical pharmacokinetics of oral fluorine anticancer medicines using the commercial MRI system 19F-MRS.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Digestive System Neoplasms; Female; Flu | 1999 |
[Home anti-cancer chemotherapy with continuous infusion of 5-FU combined with low-dose cisplatin injection via implantable venous port with portable balloon pump].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Digestive System Neoplasms; Disposa | 1999 |
[Home anti-cancer therapy with a venous port].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Costs and Cost Analysis; Digestive | 2000 |
Intestinal permeability in patients with chemotherapy-induced stomatitis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Digestive System Neoplasms | 2001 |
[Therapeutic advances in digestive oncology. III. Chemotherapy of digestive system cancers].
Topics: Adenocarcinoma; Digestive System Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Neoplas | 1979 |
A comparative study of the antitumor activities of 5'-deoxy-5-fluorouridine and its prodrug trimethoxybenzoyl-5'-deoxy-5-fluorocytidine (Ro09-1390) on human digestive organ cancer xenograft lines transplanted into nude mice.
Topics: Animals; Antineoplastic Agents; Deoxycytidine; Digestive System Neoplasms; Floxuridine; Fluorouracil | 1992 |
Decreased catabolism of fluorouracil in peripheral blood mononuclear cells during combination therapy with fluorouracil, leucovorin, and interferon alpha-2a.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid | 1992 |
[The dynamic indices of the natural killer cells in the chemotherapy of patients with digestive organ cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Digestive System Neoplasm | 1990 |
[Treatment of colorectal cancers. Recommendations of the French Foundation of Digestive Cancerology].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Digestive System Neoplasms; Fluor | 1991 |
[Induction chemotherapy in cancers of the respiratory and digestive tracts by continuous infusions combining cisplatinum (C), fluorouracil (F), bleomycin (B) or C and F].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Dige | 1986 |
[5-FU concentration in portal blood after oral administration of 1-hexylcarbamoyl-5-fluorouracil (HCFU)].
Topics: Administration, Oral; Antineoplastic Agents; Digestive System Neoplasms; Drug Combinations; Fluorour | 1988 |
[Two cases of digestive cancer demonstrated remarkable regression by hyperthermia with systemic chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Colonic N | 1989 |
[Arterial infusion cancer chemotherapy in liver tumor using implantable reservoir].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 1989 |
Species differences in substrate specificity of pyrimidine nucleoside phosphorylase.
Topics: Animals; Colon; Deoxyuridine; Digestive System; Digestive System Neoplasms; Fluorouracil; Humans; Li | 1989 |
[Chemotherapy of carcinoma of the upper respiratory and digestive tract].
Topics: Cisplatin; Combined Modality Therapy; Digestive System Neoplasms; Fluorouracil; Humans; Otorhinolary | 1986 |
[5-fluorouracil in high doses. Principles and toxicity].
Topics: Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Digestive System Neoplasms; Female; Flu | 1985 |
[High doses of 5-fluorouracil with allopurinol: doubtful therapeutic efficacy].
Topics: Allopurinol; Digestive System Neoplasms; Fluorouracil; Humans | 1985 |
[Polychemotherapy of cancer of the digestive system].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Digestive System Neop | 1985 |